Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $5.3 million.

  • Amicus Therapeutics' Other Non-Current Liabilities fell 60.69% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 60.69%. This contributed to the annual value of $7.1 million for FY2024, which is 46.57% down from last year.
  • Amicus Therapeutics' Other Non-Current Liabilities amounted to $5.3 million in Q3 2025, which was down 38.73% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Other Non-Current Liabilities peaked at $27.3 million during Q2 2021, and registered a low of $5.3 million during Q3 2025.
  • Over the past 3 years, Amicus Therapeutics' median Other Non-Current Liabilities value was $12.7 million (recorded in 2023), while the average stood at $10.6 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 50.38% in 2024, then slumped by 60.69% in 2025.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Other Non-Current Liabilities stood at $20.3 million in 2021, then grew by 5.30% to $21.4 million in 2022, then plummeted by 37.98% to $13.3 million in 2023, then tumbled by 46.57% to $7.1 million in 2024, then slumped by 60.69% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $8.6 million for Q2 2025, and $8.5 million during Q1 2025.